尼帕病毒疫苗与单克隆抗体最优部署策略建模
研究用建模评估尼帕病毒疫苗和单克隆抗体在三种暴发场景下的部署效果。结果显示当前有限暴发场景下单克隆抗体影响最大,疫苗在牲畜放大和理论持续暴发中作用显著,但均依赖快速分发。
要点
- 有限暴发中主动疫苗影响有限,单克隆抗体可大幅提升避免死亡数
- 牲畜放大和持续暴发中反应性疫苗更有效但高度依赖分发速度
- 单克隆抗体被视为当前流行病学下最具影响力的医学对策
核心结论
- 单克隆抗体是当前尼帕病毒流行病学下最具影响力的医学对策
- 疫苗在牲畜放大和理论持续暴发场景中可显著减轻疾病负担
研究设计与样本
- 建模研究评估三种暴发场景下疫苗和单克隆抗体的部署策略
- 假设单剂疫苗提供90%感染保护,考虑主动和反应性接种
主要发现
- 有限暴发中1万疗程单克隆抗体库存30年可避免49例死亡(95%CI 23-87)
- 牲畜放大暴发中反应性疫苗每万剂避免2.2例死亡(95%CI 1.6-3),总用63万剂
- 持续暴发中反应性疫苗每万剂避免467例死亡(95%CI 293-463),总用69万剂,但高度依赖交付延迟
临床怎么用
- 当前流行病学下优先储备单克隆抗体用于有限暴发
- 在牲畜放大和持续暴发场景中考虑反应性疫苗接种
- 部署策略需确保快速分发以最大化效果
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nipah virus (NiV) is endemic in Pteropus bats across South and Southeast Asia. Spillover into human populations results in usually fatal disease with the potential for human-to-human spread, which has led to NiV being classified by WHO as a priority pathogen. NiV vaccines and monoclonal antibodies (mAbs) are in development. However, it remains unclear how these medical countermeasures could be used most effectively. Here, we consider three different outbreak scenarios: limited, short-lived outbreaks as seen almost annually in Bangladesh and India; livestock amplified outbreaks as seen in Malaysia in 1998; and a third theoretical scenario of an extended outbreak caused by an evolved NiV strain with increased transmissibility. For each scenario, we considered the potential impact of a vaccine when distributed through either proactive or reactive campaigns, with a hypothetical single-dose vaccine providing 90% protection against infection. We found that, in limited scenarios, the rare nature of spillovers means proactive vaccination would have a limited impact (0.21 deaths [95%h8CI: 0.08-0.43] averted per 10,000 doses over 30 years) and require 1.2 million doses. Reactive vaccination would also have a limited impact (0.27 deaths [95%CI: 0-2.75] averted per 10,000 doses over 30 years, 31,000 doses required, equivalent to 0.9 deaths [95%CI: 0-1] averted overall) due to the limited number of transmission generations. The use of a stockpile of 10,000 therapeutic mAb regimens that could prevent death in hospitalized patients could increase the impact to 49 deaths (95%CI: 23-87) averted over 30 years. Reactive campaigns were the most effective in livestock-amplified outbreaks (2.2 deaths [95%CI: 1.6-3] averted per 10,000 doses, 630,000 doses used in total) and extended outbreaks (467 deaths [95%CI: 293-463] averted per 10,000 doses, 690,000 doses used in total) but were highly dependent on delays to vaccine delivery. These findings suggest mAbs as the most impactful medical countermeasure under current epidemiology, with vaccines playing a significant role to limit the burden from NiV in livestock amplified and in theoretical extended outbreaks. However, the impact of both medical countermeasures will rely heavily on rapid distribution.
引用
- Cortes-Azuero O, Vegvari C, Sutcliffe E, et al. Modeling optimal deployment strategies for Nipah vaccines and monoclonal antibodies. Vaccine. 2026. PMID: 42119335. doi:10.1016/j.vaccine.2026.128688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。